A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
GlaxoSmithKline
Eli Lilly and Company
Accent Therapeutics
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Revolution Medicines, Inc.
University of Colorado, Denver
GlaxoSmithKline
Novartis
Institut du Cancer de Montpellier - Val d'Aurelle
UNC Lineberger Comprehensive Cancer Center
Sahlgrenska University Hospital
Elicio Therapeutics
Institut Bergonié
University of California, San Francisco
ModeX Therapeutics, An OPKO Health Company
Esperas Pharma Inc.
Stanford University
Mayo Clinic
Universitat Jaume I
Stanford University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UTC Therapeutics Inc.
Jules Bordet Institute
Assiut University
Dublin City University
Charite University, Berlin, Germany
Corvus Pharmaceuticals, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Klus Pharma Inc.
Institut de Cancérologie de Lorraine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
MacroGenics
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Stryker Orthopaedics
Ohio State University Comprehensive Cancer Center
Imperial College London
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center
Imperial College London
Instituto do Cancer do Estado de São Paulo
University of Iowa
Ohio State University Comprehensive Cancer Center